Abstract
Resveratrol is a poly-phenol with many beneficial effects: not only as an antioxidant, anti-inflammatory, and antiatherogenic agent, as well as a platelet aggregation inhibitor, but also as an antiproliferative and proapoptotic factor in various types of cancers. There are reviews about the mechanisms responsible for its effects in leukemia and lymphomas, emphasizing the chemosensitizing role of resveratrol, which allows overcoming the multidrug resistance of cancers. The action of resveratrol occurs preferentially on leukemic cells, and not on the normal ones. In addition, it is one of the few drugs that act on leukemic stem cells. If experimental results are promising, its application in humans encounters some difficulties. The paper presents the causes of its low bioavailability, as well as recent patents that allow improvement of its bioavailability, development of new extraction procedures, obtaining new formulae, and associating resveratrol with other drugs in order to increase its effects. These patents allow optimizing its effects in order to obtain an adjuvant agent for treatment of oncohematological disorders.
Keywords: Antioxidant, apoptosis, leukemia, lymphoma, minimal residual disease, multidrug resistance, proliferation, resveratrol.
Recent Patents on Anti-Cancer Drug Discovery
Title:Could Resveratrol be a Useful Drug for the Treatment of Malignant Hemopathies?
Volume: 9 Issue: 3
Author(s): Romeo G. Mihaila
Affiliation:
Keywords: Antioxidant, apoptosis, leukemia, lymphoma, minimal residual disease, multidrug resistance, proliferation, resveratrol.
Abstract: Resveratrol is a poly-phenol with many beneficial effects: not only as an antioxidant, anti-inflammatory, and antiatherogenic agent, as well as a platelet aggregation inhibitor, but also as an antiproliferative and proapoptotic factor in various types of cancers. There are reviews about the mechanisms responsible for its effects in leukemia and lymphomas, emphasizing the chemosensitizing role of resveratrol, which allows overcoming the multidrug resistance of cancers. The action of resveratrol occurs preferentially on leukemic cells, and not on the normal ones. In addition, it is one of the few drugs that act on leukemic stem cells. If experimental results are promising, its application in humans encounters some difficulties. The paper presents the causes of its low bioavailability, as well as recent patents that allow improvement of its bioavailability, development of new extraction procedures, obtaining new formulae, and associating resveratrol with other drugs in order to increase its effects. These patents allow optimizing its effects in order to obtain an adjuvant agent for treatment of oncohematological disorders.
Export Options
About this article
Cite this article as:
Mihaila G. Romeo, Could Resveratrol be a Useful Drug for the Treatment of Malignant Hemopathies?, Recent Patents on Anti-Cancer Drug Discovery 2014; 9 (3) . https://dx.doi.org/10.2174/1574892809666140327161242
DOI https://dx.doi.org/10.2174/1574892809666140327161242 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Gene Therapy in Fanconi Anemia: A Matter of Time, Safety and Gene Transfer Tool Efficiency
Current Gene Therapy The Immunoproteasome as a Therapeutic Target for Hematological Malignancies
Current Cancer Drug Targets Strategies for Overcoming Inherent and Acquired Resistance to EGFR Inhibitors by Targeting Downstream Effectors in the RAS/PI3K Pathway
Current Cancer Drug Targets Recent Progress Toward Hydrogen Medicine: Potential of Molecular Hydrogen for Preventive and Therapeutic Applications
Current Pharmaceutical Design Moxifloxacin Based Triple Therapy as Alternative to Standard Therapy in <i>Helicobacter Pylori</i> Eradication
Anti-Infective Agents Withdrawal Notice: The Recent Advancement in the Field of Super Paramagnetic Iron Oxide Nanoparticles (SPIONs) for Aiming Breast Cancer
Current Drug Metabolism Relevance of Cytochrome P450 Polymorphisms in the Treatment of Helicobacter pylori Infection and Gastroesophageal Reflux Disease
Current Pharmacogenomics RNA Interference in Cancer: Targeting the Anti-Apoptotic Protein c-FLIP for Drug Discovery
Mini-Reviews in Medicinal Chemistry Laboratory Techniques for Human Viral Encephalitis Diagnosis
Infectious Disorders - Drug Targets Pharmacological Inhibition of Poly(ADP-ribose) Polymerase (PARP) Activity in PARP-1 Silenced Tumour Cells Increases Chemosensitivity to Temozolomide and to a N3-Adenine Selective Methylating Agent
Current Cancer Drug Targets Role of Ox-LDL and LOX-1 in Atherogenesis
Current Medicinal Chemistry New Technologies in Male Contraception
Current Women`s Health Reviews Editorial [Hot Topic:Anti-Inflammatory Strategy: Old Ally or New Promise in Therapy (Guest Editor: Marcella Reale)]
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry MicroRNA Regulation of Programmed Cell Death Pathways in Cancer
Current Chemical Biology Radioimmunotherapy of Cancer Using Monoclonal Antibodies to Target Radiotherapy
Current Pharmaceutical Design Development of <sup>18</sup>F-Labeled PET Probes for Imaging Cell Proliferation
Current Topics in Medicinal Chemistry The Dark Side of Stem Cells: Triggering Cancer Progression by Cell Fusion
Current Molecular Medicine Regulation and Importance of the PI3K/Akt/mTOR Signaling Pathway in Hematologic Malignancies
Anti-Cancer Agents in Medicinal Chemistry New Generation of Liposomal Drugs for Cancer
Anti-Cancer Agents in Medicinal Chemistry Synthetic Methods of Quinoline Derivatives as Potent Anticancer Agents
Mini-Reviews in Medicinal Chemistry